Efficacy and Limitations of Chemically Diverse Small-Molecule Enzyme-Inhibitors against the Synergistic Coagulotoxic Activities of Bitis Viper Venoms
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Snakebite remains a significant public health burden globally, disproportionately affecting low-income and impoverished regions of the world. Recently, researchers have begun to focus on the use of small-molecule inhibitors as potential candidates for the neutralisation of key snake venom toxins and as potential field therapies. Bitis vipers represent some of the most medically important as well as frequently encountered snake species in Africa, with a number of species possessing anticoagulant phospholipase A2 (PLA2) toxins that prevent the prothrombinase complex from inducing clot formation. Additionally, species within the genus are known to exert pseudo-procoagulant activity, whereby kallikrein enzymatic toxins cleave fibrinogen to form a weak fibrin clot that rapidly degrades, thereby depleting fibrinogen levels and contributing to the net anticoagulant state. Utilising well-validated coagulation assays measuring time until clot formation, this study addresses the in vitro efficacy of three small molecule enzyme inhibitors (marimastat, prinomastat and varespladib) in neutralising these aforementioned activities. The PLA2 inhibitor varespladib showed the greatest efficacy for the neutralisation of PLA2-driven anticoagulant venom activity, with the metalloproteinase inhibitors prinomastat and marimastat both showing low and highly variable degrees of cross-neutralisation with PLA2 anticoagulant toxicity. However, none of the inhibitors showed efficacy in neutralising the pseudo-procoagulant venom activity exerted by the venom of B. caudalis. Our results highlight the complex nature of snake venoms, for which single-compound treatments will not be universally effective, but combinations might prove highly effective. Despite the limitations of these inhibitors with regards to in vitro kallikrein enzyme pseudo-procoagulant venom activity, our results further support the growing body of literature indicating the potential use of small molecule inhibitors to enhance first-aid treatment of snakebite envenoming, particularly in cases where hospital and thus antivenom treatment is either unavailable or far away.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies have highlighted cross-species variation in neutralization effects of potential inhibitors, which has significant implications for the application of inhibitors as broadly effective pre-hospital treatments of envenomation by potentially diverse species (58).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [58]
In the citing paper
“inhibitors of serine proteases exist that may be effective against medically significant SVSPs”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [58]
In the citing paper
“they may also cross-react with endogenous serine proteases in human plasma, which are critical for normal coagulation cascade activation (58)”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gutiérrez, J. M., Lewin, M. R., Williams, D. J., & Lomonte, B. (2020) · Toxins · doi:10.3390/toxins12020131 · Cited by 92 · cited 1×
“Thus, current research remains primarily directed at investigating the efficacy of PLA2 and metalloprotease inhibitors [17,18,21,22,25,34].”
BackgroundSelf-citation
Research works printed but not linked: 33
- Fry, B. (2018). Snakebite: When the human touch becomes a bad touch. Toxins, 10. · DOI
- Calvete, 2017, Snakebite envenoming, Nat. Rev. Dis. Primers, 3, 17063, 10.1038/nrdp.2017.63 · DOI · Paper page
- Kasturiratne, A., Wickremasinghe, A.R., de Silva, N., Gunawardena, N.K., Pathmeswaran, A., Premaratna, R., Savioli, L., Lalloo, D.G., and de Silva, H.J. (2008). The global burden of snakebite: A literature analysis and modelling based on regional estimates of envenoming and deaths (Global Burden of Snakebite). PLoS Med., 5. · DOI · Paper page
- Williams, D.J., Faiz, M.A., Abela-Ridder, B., Ainsworth, S., Bulfone, T.C., Nickerson, A.D., Habib, A.G., Junghanss, T., Fan, H.W., and Turner, M. (2019). Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. PLoS Negl. Trop. Dis., 13. · DOI · Paper page
- Fernandez, S., Hodgson, W., Chaisakul, J., Kornhauser, R., Konstantakopoulos, N., Smith, A.I., and Kuruppu, S. (2014). In vitro toxic effects of puff adder (Bitis arietans) venom, and their neutralization by antivenom. Toxins, 6. · doi:10.3390/toxins6051586
- Lavonas, 2002, Severe puff adder (Bitis arietans) envenomation with coagulopathy, Clin. Toxicol., 40, 911
- Janette, 2016, The effect of physiological levels of South African puff adder (Bitis arietans) snake venom on blood cells: An in vitro model, Sci. Rep., 6, 35988, 10.1038/srep35988 · doi:10.1038/srep35988
- Paixão-Cavalcante, D., Kuniyoshi, A.K., Portaro FC, V., da Silva, W.D., and Tambourgi, D.V. (2015). African adders: Partial characterization of snake venoms from three Bitis species of medical importance and their neutralization by experimental equine antivenoms (Characterization of Bitis spp snake venoms). PLoS Negl. Trop. Dis., 9. · DOI
- Spawls, S., and Branch, B. (2020). The Dangerous Snakes of Africa, Bloomsbury Publishing.
- Modler, 2012, Snake bite in southern Africa: Diagnosis and management, Contin. Med. Educ., 30, 362
- Quental, 2016, Diversification in vipers: Phylogenetic relationships, time of divergence and shifts in speciation rates, Mol. Phylogenetics Evol., 105, 50, 10.1016/j.ympev.2016.07.029 · DOI · Paper page
- Barlow, 2019, Ancient habitat shifts and organismal diversification are decoupled in the African viper genus Bitis (Serpentes: Viperidae), J. Biogeogr., 46, 1234, 10.1111/jbi.13578 · DOI
- Youngman, N.J., Debono, J., Dobson, J.S., Zdenek, C.N., Harris, R.J., Brouw, B.O.D., Coimbra, F.C.P., Naude, A., Coster, K., and Sundman, E. (2019). Venomous landmines: Clinical implications of extreme coagulotoxic diversification and differential neutralization by antivenom of venoms within the Viperid snake genus Bitis. Toxins, 11. · doi:10.3390/toxins11070422
- Bulfone, 2018, Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite.(Medical condition overview), J. Trop. Med., 2018, 4320175, 10.1155/2018/4320175 · DOI · Paper page
- Albulescu, 2020, A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite, Nat. Commun., 11, 6094, 10.1038/s41467-020-19981-6 · DOI · Paper page
- Lewin, M., Samuel, S., Merkel, J., and Bickler, P. (2016). Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. Toxins, 8. · DOI · Paper page
- Bittenbinder, M.A., Zdenek, C.N., Op Den Brouw, B., Youngman, N.J., Dobson, J.S., Naude, A., Vonk, F.J., and Fry, B.G. (2018). Coagulotoxic cobras: Clinical implications of strong anticoagulant actions of African spitting Naja venoms that are not neutralised by antivenom but are by LY315920 (Varespladib). Toxins, 10. · DOI · Paper page
- Lewin, 2016, Varespladib (LY315920) appears to be a very potent, broad-spectrum, inhibitor of snake venom PLA2s from six continents, Toxicon, 117, 103, 10.1016/j.toxicon.2016.04.006 · DOI
- Wang, Y., Zhang, J., Zhang, D., Xiao, H., Xiong, S., and Huang, C. (2018). Exploration of the inhibitory potential of varespladib for snakebite envenomation. Molecules, 23. · DOI · Paper page
- Zdenek, 2020, Anticoagulant toxicity of black snake (Elapidae: Pseudechis) venoms: Potency, mechanisms, and antivenom efficacy, Toxicol. Lett., 330, 176, 10.1016/j.toxlet.2020.05.014 · DOI
- Youngman, 2020, Varespladib (LY315920) neutralises phospholipase A2 mediated prothrombinase-inhibition induced by Bitis snake venoms, Comp. Biochem. Physiol. Toxicol. Pharmacol., 236, 108818, 10.1016/j.cbpc.2020.108818 · DOI
- Chowdhury, 2021, The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms, Front. Immunol., 12, 4215, 10.3389/fimmu.2021.752442 · DOI · Paper page
- Chowdhury, 2021, Clinical implications of differential procoagulant toxicity of the Palearctic viperid genus Macrovipera, and the relative neutralization efficacy of antivenoms and enzyme inhibitors, Toxicol. Lett., 340, 77, 10.1016/j.toxlet.2020.12.019 · DOI
- Marsh, 1974, Separation and partial characterization of a coagulant enzyme from Bitis gabonica venom, Br. J. Haematol., 26, 295, 10.1111/j.1365-2141.1974.tb00474.x · doi:10.1111/j.1365-2141.1974.tb00474.x
- Pirkle, 1986, Thrombin-like enzyme from the venom of Bitis gabonica. Purification, properties, and coagulant actions, J. Biol. Chem., 261, 8830, 10.1016/S0021-9258(19)84456-3 · doi:10.1016/s0021-9258(19)84456-3
- Vaiyapuri, S., Harrison, R.A., Bicknell, A.B., Gibbins, J.M., and Hutchinson, G. (2010). Purification and functional characterisation of Rhinocerase, a novel serine protease from the venom of Bitis gabonica rhinoceros (Rhinocerase–A venom enzyme). PLoS ONE, 5. · doi:10.1371/journal.pone.0009687
- Viljoen, 1979, Separation of Bitis gabonica (Gaboon adder) venom arginine esterases into kinin-releasing, clotting and fibrinolytic factors, Toxicon, 17, 145, 10.1016/0041-0101(79)90293-9 · doi:10.1016/0041-0101(79)90293-9
- Bourke, 2020, Trimeresurus albolabris snakebite treatment implications arising from ontogenetic venom comparisons of anticoagulant function, and antivenom efficacy, Toxicol. Lett., 327, 2, 10.1016/j.toxlet.2020.03.009 · DOI
- Debono, 2019, Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors, Toxicol. Vitr., 55, 62, 10.1016/j.tiv.2018.11.008 · DOI
- Seneci, 2021, A symphony of destruction: Dynamic differential fibrinogenolytic toxicity by rattlesnake (Crotalus and Sistrurus) venoms, Comp. Biochem. Physiol. Part C Toxicol. Pharmacol., 245, 109034, 10.1016/j.cbpc.2021.109034 · DOI
- Xie, C., Albulescu, L.-O., Bittenbinder, M.A., Somsen, G.W., Vonk, F.J., Casewell, N.R., and Kool, J. (2020). Neutralizing effects of small molecule inhibitors and metal chelators on coagulopathic viperinae snake venom toxins. Biomedicines, 8. · doi:10.1101/2020.06.02.129643
- Abubakar, 2010, Amputation and disability following snakebite in Nigeria, Trop. Dr., 40, 114
- Sharma, 2004, Impact of snake bites and determinants of fatal outcomes in southeastern Nepal, Am. J. Trop. Med. Hyg., 71, 234, 10.4269/ajtmh.2004.71.234 · doi:10.4269/ajtmh.2004.71.234
Cited by
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Youngman, N. J., Lewin, M. R., Carter, R., Naude, A., & Fry, B. G.
- Affiliations
- Venom Evolution Lab, School of Biological Science, University of Queensland, St. Lucia, QLD 4072, Australia
- California Academy of Sciences, San Francisco, CA 94118, USA
- Ophirex Inc., Corte Madera, CA 94925, USA
- Snakebite Assist, Pretoria ZA-0001, South Africa
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-07
- Volume
- 27
- Issue
- 5
- Pages
- 1733
- ISSN
- 1420-3049
- Cited by
- 22
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.